Free Trial
NASDAQ:PKBO

Peak Bio 8/18/2023 Earnings Report

Peak Bio EPS Results

Actual EPS
-$0.29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Peak Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Peak Bio Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Peak Bio Earnings Headlines

The Worst Year in American Financial History?
Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behind all the chaos you've seen play out in the global economy in 2025. This curse has nothing to do with astrology or anything metaphorical. In fact, it's studied at the highest levels of finance and academia ... and VP Vance even questioned Jerome Powell about it. It's a wild money story you could soon hear everywhere. Only one investigative journalist is telling the story here.
Peak Bio Inc (PKBO)
Peak Bio, Inc. (PKBO)
See More Peak Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Peak Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Peak Bio and other key companies, straight to your email.

About Peak Bio

Peak Bio (NASDAQ:PKBO), a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

View Peak Bio Profile

More Earnings Resources from MarketBeat